Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Tax Provisions (2017 - 2025)

Karyopharm Therapeutics' Tax Provisions history spans 9 years, with the latest figure at -$67000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions rose 38.53% year-over-year to -$67000.0; the TTM value through Dec 2025 reached $43000.0, down 24.56%, while the annual FY2025 figure was $43000.0, 24.56% down from the prior year.
  • Tax Provisions reached -$67000.0 in Q4 2025 per KPTI's latest filing, down from $34000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $149000.0 in Q1 2021 to a low of -$109000.0 in Q4 2024.
  • Average Tax Provisions over 5 years is $56150.0, with a median of $60500.0 recorded in 2023.
  • Peak YoY movement for Tax Provisions: crashed 243.55% in 2021, then skyrocketed 216.85% in 2022.
  • A 5-year view of Tax Provisions shows it stood at -$89000.0 in 2021, then surged by 216.85% to $104000.0 in 2022, then increased by 25.0% to $130000.0 in 2023, then tumbled by 183.85% to -$109000.0 in 2024, then soared by 38.53% to -$67000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Tax Provisions are -$67000.0 (Q4 2025), $34000.0 (Q3 2025), and $40000.0 (Q2 2025).